Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target increased by equities research analysts at Royal Bank Of Canada from $195.00 to $258.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 13.68% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the company. Leerink Partners lifted their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Piper Sandler lifted their target price on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. TD Cowen lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $230.56.

Jazz Pharmaceuticals Stock Down 0.7%

NASDAQ JAZZ opened at $226.96 on Wednesday. The company has a current ratio of 2.04, a quick ratio of 1.67 and a debt-to-equity ratio of 0.95. The stock’s 50 day moving average is $192.62 and its two-hundred day moving average is $172.95. The company has a market capitalization of $14.24 billion, a price-to-earnings ratio of -11,342.33, a PEG ratio of 0.40 and a beta of 0.27. Jazz Pharmaceuticals has a 1-year low of $97.50 and a 1-year high of $230.40.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Equities analysts forecast that Jazz Pharmaceuticals will post 20.51 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the transaction, the director owned 7,024 shares in the company, valued at $1,348,608. The trade was a 32.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,287 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the transaction, the chief accounting officer owned 6,512 shares of the company’s stock, valued at $1,191,305.28. This trade represents a 16.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 74,015 shares of company stock worth $14,180,486 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $127,344,000. Goldentree Asset Management LP bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $149,597,000. Franklin Resources Inc. raised its position in shares of Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after acquiring an additional 1,129,995 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Jazz Pharmaceuticals by 160.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after acquiring an additional 715,361 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Jazz Pharmaceuticals by 258.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after acquiring an additional 395,000 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q1 sales beat expectations — Jazz reported Q1 results that surprised the market, with revenue growth driven by core neurology and oncology franchises. Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
• Positive Sentiment: Revenue strength: Q1 revenues rose ~19%, helped by Xywav, Epidiolex and oncology product growth — a core driver behind the upside reaction. JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
• Positive Sentiment: Management reaffirmed 2026 revenue guidance ($4.25B–$4.5B) and reiterated a targeted Aug. 25, 2026 PDUFA for Ziihera in GEA — a near-term approval catalyst. Jazz reaffirms $4.25B-$4.5B 2026 revenue guidance while targeting an Aug. 25, 2026 PDUFA for Ziihera in GEA
• Positive Sentiment: Analysts raised targets and ratings — Wells Fargo lifted its PT to $265 (overweight) and RBC raised its target to $258 (outperform), signaling institutional buy-side conviction that shares have meaningful upside. Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $265.00 at Wells Fargo & Company Royal Bank Of Canada Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price
• Neutral Sentiment: Earnings call transcript and deeper metrics are available for investors deciding whether the beat is durable — read the full call and metric breakdown to assess margin and pipeline cadence. Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst and media deep-dives highlight an oncology pivot that some believe the market still underappreciates — useful context but mixed on timing of commercial ramp and approvals. Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
• Negative Sentiment: Some analysts remain conflicted — a roundup shows mixed sentiment across firms, which can increase volatility and put near-term pressure on the stock despite positive fundamentals. Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY) and Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.